SAN DIEGO, CA, June, 17, 2021 — SMSbiotech announced today that French virologist and Nobel laureate, Luc Montagnier M.D., PhD., has joined the company as an advisory board member. Professor Montagnier has a wealth of knowledge he is able to lend to the research and development of Small Mobile Stem (SMS) cell therapies leading to new regenerative medicine solutions.
In 1983, Professor Montagnier led the team which first isolated the Human Immunodeficiency Virus/HIV1, the causative agent of AIDS. Two years later he also isolated the second AIDS virus, HIV2, from West African patients.
Beside his involvement in the design of new types of therapeutic HIV vaccines, he currently studies the diagnosis and treatment of microbial and viral factors associated with cancers, neurodegenerative and articular diseases, using innovative technologies. As a strong advocate of preventive medicine, he is especially concerned with prolonging the active life of aging people.
Beyond his scientific interest is his deep involvement with helping developing countries to acquire knowledge of and access to modern and preventive medicine. As President of the World Foundation for Aids Research and Prevention, he has co-founded two Centers for the prevention, treatment, research and diagnosis of AIDS patients in Ivory Coast and Cameroon.
Ten years ago, Professor Montagnier co-founded CHRONIMED, an international group of physicians treating chronic diseases, including but not limited to autism spectrum diseases, Alzheimer’s, Lyme, multiple sclerosis, and cancer.
“Chronic degenerative diseases are critical challenges of epidemiological proportions. They require the best multidisciplinary efforts, and all the dedication we can amass” says Dr. A. Rahmo CSO of SMSbiotech ” Indeed professor Montagnier’s knowledge in chronic diseases and experience in preventive medicine is a great asset to the SMSbiotech team as they move towards advancing the field of regenerative medicine”.
SMSbiotech Inc. is an early-stage C-Corp based in San Marcos, California. SMSbiotech’s vision is to build a new generation of effective biotherapies that are affordable and available to the masses, utilizing its unique platform technology.
About Platform Technology of SMSbiotech
SMSbiotech has developed a proprietary technology for manufacturing allogeneic SMS cells and derivatives at industrial scale. SMS cells are human adult stem cells with unique characteristics that make them conducive to large scale, therapeutic applications. This technology will address diverse indications related to regenerative medicine.
Richard Borror, CEO
Abdulkader Rahmo, CSO